Poolbeg Pharma Plc
Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
By Elric Langton | 14 December 2022
I have a financial interest in Poolbeg Pharma.
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a leading infectious disease-focused biopharmaceutical Company, has announced has signed an exclusive licence with InsuCaps (the sister company of our Oral Vaccine Platform partner Anabio) to use its microencapsulation and nanoencapβ¦